This HTML5 document contains 120 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00434/identifier/pubchem-substance/
n17http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00434/identifier/drugbank/
n6http://linked.opendata.cz/resource/drugbank/company/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00434/identifier/iuphar/
n14http://linked.opendata.cz/resource/drugbank/dosage/
n13http://linked.opendata.cz/resource/drugbank/mixture/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00434/identifier/guide-to-pharmacology/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00434/identifier/national-drug-code-directory/
n24http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00434/identifier/chemspider/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00434/identifier/chebi/
n30http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://www.drugs.com/cdi/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00434/identifier/pharmgkb/
n11http://www.rxlist.com/cgi/generic2/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00434/identifier/wikipedia/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00434/identifier/bindingdb/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00434/identifier/pubchem-compound/
n16http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00434
rdf:type
n3:Drug
n3:description
A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc. [PubChem]
n3:dosage
n14:271B4DB6-363D-11E5-9242-09173F13E4C5 n14:271B4DB5-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Tokunaga S, Takeda Y, Shinomiya K, Hirase M, Kamei C: Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats. J Pharmacol Sci. 2007 Feb;103(2):201-6. Epub 2007 Feb 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17287588
n3:group
approved
n3:indication
For treatment of perennial and seasonal allergic rhinitis, vasomotor rhinitis, allergic conjunctivitis due to inhalant allergens and foods, mild uncomplicated allergic skin manifestations of urticaria and angioedema, amelioration of allergic reactions to blood or plasma, cold urticaria, dermatographism, and as therapy for anaphylactic reactions adjunctive to epinephrine.
n3:manufacturer
n6:271B4DB0-363D-11E5-9242-09173F13E4C5
owl:sameAs
n24:DB00434 n30:DB00434
dcterms:title
Cyproheptadine
adms:identifier
n10:PA164749366 n12:Cyproheptadine n18:4046 n19:2810 n20:50017721 n21:277 n22:277 n25:DB00434 n27:2913 n28:46508613 n29:49884-043-01
n3:mechanismOfAction
Cyproheptadine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. Cyproheptadine also competes with serotonin at receptor sites in smooth muscle in the intestines and other locations. Antagonism of serotonin on the appetite center of the hypothalamus may account for Cyproheptadine's ability to stimulate appetite.
n3:packager
n6:271B4D93-363D-11E5-9242-09173F13E4C5 n6:271B4D91-363D-11E5-9242-09173F13E4C5 n6:271B4D92-363D-11E5-9242-09173F13E4C5 n6:271B4D8F-363D-11E5-9242-09173F13E4C5 n6:271B4D90-363D-11E5-9242-09173F13E4C5 n6:271B4D8D-363D-11E5-9242-09173F13E4C5 n6:271B4D8E-363D-11E5-9242-09173F13E4C5 n6:271B4D8B-363D-11E5-9242-09173F13E4C5 n6:271B4D8C-363D-11E5-9242-09173F13E4C5 n6:271B4DAE-363D-11E5-9242-09173F13E4C5 n6:271B4DAF-363D-11E5-9242-09173F13E4C5 n6:271B4DAC-363D-11E5-9242-09173F13E4C5 n6:271B4DAD-363D-11E5-9242-09173F13E4C5 n6:271B4DAA-363D-11E5-9242-09173F13E4C5 n6:271B4DAB-363D-11E5-9242-09173F13E4C5 n6:271B4DA8-363D-11E5-9242-09173F13E4C5 n6:271B4DA9-363D-11E5-9242-09173F13E4C5 n6:271B4DA6-363D-11E5-9242-09173F13E4C5 n6:271B4DA7-363D-11E5-9242-09173F13E4C5 n6:271B4DA4-363D-11E5-9242-09173F13E4C5 n6:271B4DA5-363D-11E5-9242-09173F13E4C5 n6:271B4DA2-363D-11E5-9242-09173F13E4C5 n6:271B4DA3-363D-11E5-9242-09173F13E4C5 n6:271B4DA0-363D-11E5-9242-09173F13E4C5 n6:271B4DA1-363D-11E5-9242-09173F13E4C5 n6:271B4D9E-363D-11E5-9242-09173F13E4C5 n6:271B4D9F-363D-11E5-9242-09173F13E4C5 n6:271B4D9C-363D-11E5-9242-09173F13E4C5 n6:271B4D9D-363D-11E5-9242-09173F13E4C5 n6:271B4D9A-363D-11E5-9242-09173F13E4C5 n6:271B4D9B-363D-11E5-9242-09173F13E4C5 n6:271B4D98-363D-11E5-9242-09173F13E4C5 n6:271B4D99-363D-11E5-9242-09173F13E4C5 n6:271B4D96-363D-11E5-9242-09173F13E4C5 n6:271B4D97-363D-11E5-9242-09173F13E4C5 n6:271B4D94-363D-11E5-9242-09173F13E4C5 n6:271B4D95-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
After a single 4 mg oral dose of14C-labelled cyproheptadine HCl in normal subjects, given as tablets 2% to 20% of the radioactivity was excreted in the stools. At least 40% of the administered radioactivity was excreted in the urine.
n3:synonym
4-(5H-Dibenzo(a,D)cyclohepten-5-ylidene)-1-methylpiperidine Cyproheptadinum 4-(5-Dibenzo(a,D)cyclohepten-5-ylidine)-1-methylpiperidine Ciproheptadina Cyproheptadin 1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine 5-(1-methylpiperidylidene-4)-5H-dibenzo(a,d)cyclopheptene Dihexazin 1-Methyl-4-(5H-dibenzo(a,d)cycloheptenylidene)piperidine Cyproheptadine 4-Dibenzo[a,D]cyclohepten-5-ylidene-1-methyl-piperidine Axoprol Glutodina
n15:hasAHFSCode
n17:04-04-92
n3:foodInteraction
Avoid alcohol. Take with food.
n3:mixture
n13:271B4D8A-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
96 to 99%
n3:salt
n3:synthesisReference
Engelhardt, E.L.; U S . Patent 3,014,911; December 26, 1961; assigned to Merck & Co., Inc.
foaf:page
n8:cyproheptadine.html n11:cyprohept.htm
n3:IUPAC-Name
n4:271B4DBB-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4DC1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4DC0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4DBD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4DBE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4DBF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4DD0-363D-11E5-9242-09173F13E4C5 n4:271B4DB9-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4DBA-363D-11E5-9242-09173F13E4C5 n4:271B4DD2-363D-11E5-9242-09173F13E4C5 n4:271B4DB7-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4DB8-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n16:R06AX02
n3:H-Bond-Acceptor-Count
n4:271B4DC7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4DC8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4DC2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4DC3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4DC5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4DC4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4DC6-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed after oral administration.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
129-03-3
n3:category
n3:containedIn
n5:271B4DB3-363D-11E5-9242-09173F13E4C5 n5:271B4DB4-363D-11E5-9242-09173F13E4C5 n5:271B4DB1-363D-11E5-9242-09173F13E4C5 n5:271B4DB2-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4DCC-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4DCE-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4DCF-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4DD1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4DCB-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4DCA-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4DCD-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4DBC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4DC9-363D-11E5-9242-09173F13E4C5